Neuropathic pain is pain caused by a lesion or disease of the somatosensory nervous system. It is one of the areas in which cannabinoids have been investigated most extensively. There is a biological rationale, along with controlled human studies suggesting a modest benefit for some patients. But response varies, products differ, and side effects matter.
When the alarm system itself becomes faulty
Imagine a home alarm. It should sound when someone breaks in. But if it goes off without an intruder, the problem lies in the alarm itself. Pain from tissue injury often serves as a warning; neuropathic pain can arise because the nerves that transmit sensation have themselves been damaged or altered. Abnormal signals may persist even without new damage.
What does neuropathic pain feel like?
People describe burning, electric shocks, stabbing sensations, tingling, pins and needles, painful cold, and sensitivity to touch. Even a bedsheet may hurt. Pain caused by a stimulus that would not normally be painful is known as allodynia.
What causes it?
Examples include diabetic neuropathy, nerve injury after surgery, traumatic injury, shingles, spinal cord injury, multiple sclerosis, some chemotherapy drugs and nerve-root compression. These conditions differ, but each can damage the pathways responsible for transmitting sensation.
Why is it so difficult to treat?
The source of the problem may not be where the pain is felt. Burning in a foot can originate in the peripheral nerve or in central pain processing. Over time, the spinal cord and brain may become sensitized: the threshold for generating pain falls, and incoming signals become amplified. A treatment aimed only at local inflammation may therefore be insufficient.
The endocannabinoid system enters the picture
Cannabinoid receptors occur at several stages of pain signaling: sensory neurons, dorsal-root ganglia, spinal cord and brain. Experimental studies have documented changes in endocannabinoid concentrations and receptor expression after nerve injury. This suggests that the body's own cannabinoid system is involved in regulating pain, but does not by itself demonstrate that a cannabis product will treat a patient's condition.
CB1: reducing neural signal transmission
Activation of CB1 can decrease release of certain neurotransmitters. In the context of neuropathic pain, that may lower the volume of pain transmission or change how a signal is processed. Importantly, lowering the signal is not equivalent to repairing the nerve.
CB2: inflammation and immune cells
Nerve injury may also trigger inflammatory responses involving immune cells and microglia. CB2 is associated with the regulation of immune-cell activity and inflammatory mediators. The potential involvement of CB1 in neuronal signaling and CB2 in inflammatory processes is one reason researchers have studied cannabinoids in neuropathic pain.
What have human trials shown?
Several randomized controlled trials found pain reductions in subsets of people using vaporized or other THC-containing cannabis preparations, compared with placebo. One examined central and peripheral neuropathic pain with relatively low-dose vaporized cannabis; another examined post-traumatic or postsurgical neuropathic pain. Individual trials can be informative, but the wider evidence must also be considered.
What happens when studies are assessed together?
The 2024 AHRQ living systematic review included many trials involving neuropathic pain. For certain preparations with comparable THC:CBD content, average pain improvements were small, and adverse effects such as dizziness, sedation and nausea increased. The evidence does not justify saying that cannabis eliminates neuropathic pain. A more defensible conclusion is that some cannabinoids provide modest relief to some patients, with trade-offs.
Why might a small improvement matter?
For someone experiencing pain every day, even partial relief—particularly if it allows better sleep or movement—may improve quality of life. Relevant goals include walking, working, sleeping, leaving home and reducing the burden that pain places on ordinary activities. Pain scores alone cannot describe all of these changes.
THC versus CBD
Much of the clinical evidence for pain relief comes from products containing THC, sometimes combined with CBD. In the AHRQ review, oral CBD alone did not consistently reduce pain. This does not establish that CBD has no value, but neither does it support advertising every CBD oil as a proven neuropathic-pain treatment.
Why not increase the THC dose indefinitely?
Higher exposure may cause more dizziness, drowsiness, impaired attention and short-term memory, confusion or reduced coordination. The goal is not the largest possible dose: it is an acceptable balance between relief and day-to-day function, with clinical oversight.
Can cannabis heal a damaged nerve?
Less pain does not mean that the cause of neuropathy has disappeared. Cannabis has not been generally proven to regenerate damaged human nerves or cure neuropathy. Someone with diabetic neuropathy may feel meaningful relief while still requiring treatment for diabetes and the underlying metabolic disorder.
Different neuropathies, different outcomes
Chemotherapy-related neuropathy, diabetic neuropathy, post-herpetic neuralgia and spinal cord injury are not identical diseases. Research is still insufficient to establish which subgroups benefit most. It is also difficult to compare studies when THC:CBD ratios, oral versus inhaled use and product composition differ. Psychoactive effects can make blinding against placebo difficult.
The bottom line
The endocannabinoid system has plausible roles in neural pain signaling and neuroimmune responses. Controlled trials suggest that certain cannabinoid formulations can yield modest relief for some patients with neuropathic pain. They do not establish a cure, guaranteed benefit, or equivalence among cannabis products. Careful attention to adverse effects, existing therapies and meaningful functional goals remains essential.
Scientific sources
- Chou R, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update. AHRQ.
Find this source ↗ - Wilsey B, et al. Low Dose Vaporized Cannabis Significantly Improves Neuropathic Pain.
Find this source ↗ - Ware MA, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.
Find this source ↗ - The Endocannabinoid System and Pain.
Find this source ↗ - International Association for the Study of Pain. Cannabinoids and Pain Position Statement.
Find this source ↗
Ask about individual guidance
Speak with our team to find out whether guidance is appropriate for your situation.
WhatsApp ↗